Profiles
Lou Roddam
UTAS Home Dr Louise Roddam
Louise Roddam
Senior Lecturer in Biochemistry & Molecular Biology
Room 240-03 , Medical Science 2
+61 3 6226 4889 (phone)
Dr Louise Roddam is currently employed by the University of Tasmania and is an Honorary Associate of the Menzies Institute for Medical Research. She is co-leader of the Host-Pathogen Interactions Group and chair of the Tasmanian branch of the Australian Society for Microbiology. Dr Roddam teaches biochemistry, genetics, molecular biology, and protein chemistry. Prior to 2005 she trained as an NHMRC post-doctoral scientist in the University of Queensland Molecular Microbiology laboratory.
Biography
Dr Lousie Roddam trained in two leading laboratories in microbial pathogenesis, one at the Australian National University, the second at the University of Queensland and has a strong research history focused on using molecular techniques to examine host-pathogen interactions.
Memberships
Professional practice
- Member of the National Scientific Advisory Council for the Australian Society for Microbiology (ASM) (2010-2012)
- Scientific Division 4 co-chair (Molecular Microbiology) for the 2011 ASM national conference (2010 - 2012)
Committee associations
- Scientific Advisor on Tasmanian Human Research Ethics Committee (2013 - current)
- Chair of Tasmanian Branch of ASM (2007- current)
- Member of the UTas Institutional Biosafety Committee (IBC) (2008 - current)
Administrative expertise
Panel member:
- NHMRC (2012- current)
- Channel 7 Children's Research Foundation (2012)
Conference Organisation:
- Co-conference covenor, Australian Society for Microbiology (ASM) Bistate conference (Hobart 2009, 2012)
- Member of Local Organising Committee (LOC) of ASM National meeting (Hobart, 2011)
- Member of 13th International Conference on Pseudomonas LOC (Sydney, 2011)
Teaching
Molecular Biology, Cellular Biology, Microbiology, Biochemistry, Immunology, Cystic Fibrosis
Teaching expertise
Dr Roddam currently teaches in a range of subjects offered through the School of Medicine. As a teacher Dr Roddam enjoys witnessing student progression as they learn, integrate and synthesise knowledge. A particular interest of Dr Roddam's is the integration of research skills into undergraduate courses.
Teaching responsibility
Unit Coordinator:
Units Contributed to:
- Biochemistry A (Pharmacy) (CBA221)
- Biochemistry B (Pharmacy) (CBA222)
- Biochemistry: Metabolism & Nutrition (CBA260)
- Molecular Biology in Health & Disease (CBA265)
- Molecular Biology & Protein Biochemistry (CBA341)
- Techniques in Molecular Biology & Protein Biochemistry (CBA342)
- Research Project in Health & Disease (CBA344)
- Advanced Immunology (CJA314)
Research Invitations
Dr Roddam has been invited to give the following conference symposium presentations:
- 'What can we learn from in vivo transcript analysis of clinical CF samples?' at the National Meeting of the Australian Society for Microbiology, Brisbane 2012
- 'Microbiology and immune modulation during intravenous antibiotic therapy' at the National Meeting of the Australian Society for Microbiology, Brisbane 2012
View more on Dr Louise Roddam in WARP
Expertise
Dr Roddam's expertise lies in:
- Host-pathogen interactions
- Bacterial biofilms
- Lung infections in cystic fibrosis
- Pseudomonas aeruginosa
- Molecular biology and gene expression analysis
- Microbiology
- Tissue culture
- Protein purification and proteomics
Research Themes
Dr Roddam's research is aligned with the University's research theme of Better Health. Her work focusses on molecular aspects of bacterial virulence, with a strong interest in developing novel therapies targeting chronic infections in the lungs of people with cystic fibrosis (CF).
Awards
- Royal Hobart Hospital Research Foundation Fellowship (2006)
- Unit-based Teaching Merit Certificate (Immunology and Medical Microbiology) (2005)
- Australian National University Scholarship (1994)
Current projects
Dr Roddam's current research focusses on bacterial-host interactions and the development of an anti-pseudomonal therapy with the aim of preventing/treating chronic lung infections for people with cystic fibrosis (CF), infections that are associated with significant morbidity and mortality.
Fields of Research
- Medical bacteriology (320701)
- Respiratory diseases (320103)
- Clinical microbiology (320203)
- Infectious diseases (320211)
- Innate immunity (320407)
- Medical biochemistry and metabolomics (320599)
- Infectious agents (310702)
- Systems biology (310114)
- Microbial genetics (310704)
- Neurology and neuromuscular diseases (320905)
- Structural biology (incl. macromolecular modelling) (310112)
- Enzymes (310106)
- Immunology (320499)
- Preventative health care (420605)
- Cellular nervous system (320902)
- Cardiovascular medicine and haematology (320199)
- Pharmacology and pharmaceutical sciences (321499)
- Mycology (310705)
- Medical genetics (excl. cancer genetics) (320213)
- Bacteriology (310701)
- Cellular immunology (320404)
- Central nervous system (320903)
- Pharmaceutical sciences (321405)
- Medical microbiology (320799)
- Dermatology (320205)
- Microbial ecology (310703)
- Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) (320402)
- Otorhinolaryngology (320217)
Research Objectives
- Clinical health (200199)
- Expanding knowledge in the health sciences (280112)
- Human pharmaceutical treatments (240803)
- Expanding knowledge in the biological sciences (280102)
- Expanding knowledge in the environmental sciences (280111)
- Other health (209999)
- Expanding knowledge in the agricultural, food and veterinary sciences (280101)
- Human pharmaceutical products (240899)
- Treatment of human diseases and conditions (200105)
Publications
Dr Roddam reviews papers for several international journals (Journal of Molecular Microbiology and Biotechnology, Journal of Cystic Fibrosis, Microbiology).
Total publications
38
Journal Article
(27 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2020 | Pitt ME, Nguyen SH, Duarte TPS, Roddam LF, Blaskovich MAT, et al., 'Complete genome sequences of clinical Pandoraea fibrosis isolates', Microbiology Resource Announcements, 9, (13) pp. 1-3. ISSN 2576-098X (2020) [Refereed Article] DOI: 10.1128/MRA.00060-20 [eCite] [Details] Citations: Scopus - 1Web of Science - 1 | |
| 2019 | Mulcahy EM, Cooley MA, McGuire H, Asad S, Fazekas de St Groth B, et al., 'Widespread alterations in the peripheral blood innate immune cell profile in cystic fibrosis reflect lung pathology', Immunology and Cell Biology pp. 1-11. ISSN 0818-9641 (2019) [Refereed Article] DOI: 10.1111/imcb.12230 [eCite] [Details] Citations: Scopus - 5Web of Science - 5 Co-authors: Cooley MA; Beggs SA | |
| 2019 | See-Too WS, Ambrose M, Malley R, Ee R, Mulcahy-Singh EM, et al., 'Pandoraea fibrosis sp. nov., a novel Pandoraea species isolated from clinical respiratory samples', International Journal of Systematic and Evolutionary Microbiology, 69, (3) pp. 645-651. ISSN 1466-5026 (2019) [Refereed Article] DOI: 10.1099/ijsem.0.003147 [eCite] [Details] Citations: Scopus - 9Web of Science - 11 Co-authors: Ambrose M; Malley R; Mulcahy-Singh EM; Pagnon JC | |
| 2018 | Yen S, Preissner M, Bennett E, Dubsky S, Carnibella R, et al., 'The link between regional tidal stretch and lung injury during mechanical ventilation', American Journal of Respiratory Cell and Molecular Biology pp. 1-35. ISSN 1535-4989 (2018) [Refereed Article] DOI: 10.1165/rcmb.2018-0143OC [eCite] [Details] Citations: Scopus - 20Web of Science - 16 Co-authors: Yen S; Bennett E; O'Toole R; Dargaville PA; Zosky GR | |
| 2017 | Corley SM, MacKenzie KL, Beverdam A, Roddam LF, Wilkins MR, 'Differentially expressed genes from RNASeq and functional enrichment results are affected by the choice of single-end versus paired-end reads and stranded versus non-stranded protocols', Bmc Genomics, 18 pp. 1-13. ISSN 1471-2164 (2017) [Refereed Article] DOI: 10.1186/s12864-017-3797-0 [eCite] [Details] Citations: Scopus - 17Web of Science - 18 | |
| 2016 | Ambrose M, Malley RC, Warren SJ, Beggs SA, Swallow OFE, et al., 'Pandoraea pnomenusa isolated from an Australian patient with cystic fibrosis', Frontiers in microbiology, 7 Article 692. ISSN 1664-302X (2016) [Refereed Article] DOI: 10.3389/fmicb.2016.00692 [eCite] [Details] Citations: Scopus - 9Web of Science - 9 Co-authors: Ambrose M; Malley RC; Beggs SA | |
| 2015 | Ee R, Ambrose M, Lazenby C, Williams P, Chan K-G, et al., 'Genome sequences of two Pandoraea pnomenusa isolates recovered 11 months apart from a cystic fibrosis patient', Genome Announcements, 3, (1) Article e01389-14. ISSN 2169-8287 (2015) [Refereed Article] DOI: 10.1128/genomeA.01389-14 [eCite] [Details] Citations: Scopus - 10 Co-authors: Ambrose M | |
| 2015 | Gizdavic-Nikolaidis MR, Pagnon JC, Ali N, Sum R, Davies N, et al., 'Functionalized polyanilines disrupt Pseudomonas aeruginosa and Staphylococcus aureus biofilms', Colloids and Surfaces B: Biointerfaces, 136 pp. 666-673. ISSN 0927-7765 (2015) [Refereed Article] DOI: 10.1016/j.colsurfb.2015.10.015 [eCite] [Details] Citations: Scopus - 22Web of Science - 20 Co-authors: Pagnon JC; Ali N; Davies N; Ambrose M | |
| 2015 | Mulcahy-Singh EM, Hudson JB, Beggs SA, Reid DW, Roddam LF, et al., 'High peripheral blood Th17 percent associated with poor lung function in cystic fibrosis', PLoS One, 10, (3) Article e0120912. ISSN 1932-6203 (2015) [Refereed Article] DOI: 10.1371/journal.pone.0120912 [eCite] [Details] Citations: Scopus - 26Web of Science - 24 Co-authors: Mulcahy-Singh EM; Hudson JB; Beggs SA; Reid DW; Cooley MA | |
| 2013 | Konings AF, Martin LW, Sharples MJ, Roddam LF, Latham R, et al., 'Pseudomonas aeruginosa uses multiple pathways to acquire iron during chronic infection in cystic fibrosis lungs', Infection and Immunity, 81, (8) pp. 2697-2704. ISSN 0019-9567 (2013) [Refereed Article] DOI: 10.1128/IAI.00418-13 [eCite] [Details] Citations: Scopus - 86Web of Science - 79 Co-authors: Latham R; Reid DW | |
| 2013 | Reid DW, Latham R, Lamont IL, Camara M, Roddam LF, 'Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis', Journal of Cystic Fibrosis, 12, (6) pp. 688-699. ISSN 1569-1993 (2013) [Refereed Article] DOI: 10.1016/j.jcf.2013.03.008 [eCite] [Details] Citations: Scopus - 17Web of Science - 17 Co-authors: Reid DW; Latham R | |
| 2012 | Griffin PE, Roddam LF, Belessis YC, Strachan R, Beggs S, et al., 'Expression of PPARγ and Paraoxonase 2 correlated with Pseudomonas aeruginosa infection in Cystic Fibrosis', PLoS One, 7, (7) Article e42241. ISSN 1932-6203 (2012) [Refereed Article] DOI: 10.1371/journal.pone.0042241 [eCite] [Details] Citations: Scopus - 23Web of Science - 23 Co-authors: Griffin PE; Beggs S; Cooley MA | |
| 2012 | Wood-Baker R, Tristram S, Latham R, Haug G, Reid D, et al., 'Molecular detection of Haemophilus influenzae in COPD sputum is superior to conventional culturing methods', British Journal of Biomedical Science, 69, (1) pp. 37-39. ISSN 0967-4845 (2012) [Refereed Article] DOI: 10.1080/09674845.2012.11978244 [eCite] [Details] Citations: Scopus - 4Web of Science - 4 Co-authors: Wood-Baker R; Tristram S; Latham R; Reid D | |
| 2011 | Bradbury RS, Tristram SG, Roddam LF, Reid DW, Inglis TJJ, et al., 'Antimicrobial susceptibility testing of cystic fibrosis and non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa: a comparison of three methods', British Journal of Biomedical Science, 68, (1) pp. 1-4. ISSN 0967-4845 (2011) [Refereed Article] DOI: 10.1080/09674845.2011.11732833 [eCite] [Details] Citations: Scopus - 6Web of Science - 6 Co-authors: Bradbury RS; Tristram SG; Reid DW; Champion AC | |
| 2011 | Jennings MP, Jen FE, Roddam LF, Apicella MA, Edwards JL, 'Neisseria gonorrhoeae pilin glycan contributes to CR3 activation during challenge of primary cervical epithelial cells', Cellular Microbiology, 13, (6) pp. 885-896. ISSN 1462-5814 (2011) [Refereed Article] DOI: 10.1111/j.1462-5822.2011.01586.x [eCite] [Details] Citations: Scopus - 62Web of Science - 59 | |
| 2010 | Anderson R, Roddam LF, Bettiol SS, Sanderson Kevin, Reid DW, 'Biosignificance of bacterial cyanogenesis in the CF lung', Journal of Cystic Fibrosis, 9, (3) pp. 158-164. ISSN 1569-1993 (2010) [Refereed Article] DOI: 10.1016/j.jcf.2009.12.003 [eCite] [Details] Citations: Scopus - 25Web of Science - 26 Co-authors: Anderson R; Bettiol SS; Sanderson Kevin; Reid DW | |
| 2010 | Bradbury RS, Roddam LF, Merritt A, Reid DW, Champion AC, 'Virulence gene distribution in clinical, nosocomial and environmental isolates of Pseudomonas aeruginosa', Journal of Medical Microbiology, 59, (8) pp. 881-890. ISSN 0022-2615 (2010) [Refereed Article] DOI: 10.1099/jmm.0.018283-0 [eCite] [Details] Citations: Scopus - 81Web of Science - 73 Co-authors: Bradbury RS; Reid DW; Champion AC | |
| 2009 | O'May C, Sanderson K, Roddam LF, Kirov SM, Reid DW, 'Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions', Journal of Medical Microbiology, 58, (6) pp. 765-773. ISSN 0022-2615 (2009) [Refereed Article] DOI: 10.1099/jmm.0.004416-0 [eCite] [Details] Citations: Scopus - 86Web of Science - 78 Co-authors: O'May C; Sanderson K; Kirov SM; Reid DW | |
| 2009 | Reid DW, O'May C, Kirov SM, Roddam LF, Lamont IL, et al., 'Iron chelation directed against biofilms as an adjunct to conventional antibiotics', American Journal of Physiology: Lung Cellular and Molecular Physiology, 296, (5) pp. 857-858. ISSN 1040-0605 (2009) [Letter or Note in Journal] Co-authors: Reid DW; O'May C; Kirov SM; Sanderson Kevin | |
| 2009 | Reid DW, O'May C, Roddam LF, Lamont IL, 'Chelated iron as an anti-Pseudomonas aeruginosa biofilm therapeutic strategy', Journal of Applied Microbiology, 106, (3) pp. 1058. ISSN 1364-5072 (2009) [Letter or Note in Journal] Co-authors: Reid DW; O'May C | |
| 2005 | Paton AW, Jennings MP, Morona R, Wang H, Forareta A, et al., 'Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea ', Gastroenterology, 128, (5) pp. 1219-1228. ISSN 0016-5085 (2005) [Refereed Article] DOI: 10.1053/j.gastro.2005.01.050 [eCite] [Details] Citations: Scopus - 81Web of Science - 73 | |
| 2004 | Warren MJ, Roddam LF, Power PM, Terry TD, Jennings MP, 'Analysis of the role of pglI in pilin glycosylation of Neisseria meningitidis', FEMS Immunology and Medical Microbiology, 41, (1) pp. 43-50. ISSN 0928-8244 (2004) [Refereed Article] DOI: 10.1016/j.femsim.2004.01.002 [eCite] [Details] Citations: Scopus - 31Web of Science - 30 | |
| 2003 | Dieckelmann M, Roddam LF, Jennings MP, 'Purification of post-translationally modified proteins from bacteria:: Homologous expression and purification of histidine-tagged pilin from neisseria meningitidis', Protein Expression and Purification, 30, (1) pp. 69-77. ISSN 1046-5928 (2003) [Refereed Article] DOI: 10.1016/S1046-5928(03)00061-5 [eCite] [Details] Citations: Scopus - 6Web of Science - 4 | |
| 2003 | Power PM, Roddam LF, Rutter K, Fitzpatrick SZ, Srikhanta YN, et al., 'Genetic characterization of pilin glycosylation and phase variation in Neisseria meningitidis', Molecular Microbiology, 49, (3) pp. 833-847. ISSN 0950-382X (2003) [Refereed Article] DOI: 10.1046/j.1365-2958.2003.03602.x [eCite] [Details] Citations: Scopus - 106Web of Science - 103 | |
| 2002 | Roddam LF, Lewis-Henderson W, Djordjevic M, 'Two novel chromosomal loci influence cultivar-specific nodulation failure in the interaction between strain ANU794 and subterranean clover cv. Woogenellup', Functional Plant Biology: An International Journal of Plant Function, 29 pp. 473-483. ISSN 1445-4408 (2002) [Refereed Article] | |
| 2000 | Power PM, Roddam LF, Dieckelmann M, Srikhanta YN, Tan YC, et al., 'Genetic characterization of pilin glycosylation in Neisseria meningitidis', Microbiology, 146, (4) pp. 967-979. ISSN 0026-2617 (2000) [Refereed Article] | |
| 1997 | Roddam LF, Rath A, 'Isolation and characterisation of Metarhizium anisopliae and Beauveria bassiana from subantarctic Macquarie Island', Journal of Invertebrate Pathology: Devoted to The Pathology and Microbiology of Insects and Other Invertebrates, 69 pp. 285-288. ISSN 0022-2011 (1997) [Refereed Article] |
Conference Publication
(11 outputs)| Year | Citation | Altmetrics |
|---|---|---|
| 2016 | Ambrose M, Pagnon JC, Roddam LF, 'Regulation of mutagenesis in Pseudomonas aeruginosa', Molecular Genetics of Bacteria and Phages Meeting, 8-12 August, 2016, University of Wisconsin, Madison, USA (2016) [Conference Extract] Co-authors: Ambrose M; Pagnon JC | |
| 2013 | Roddam LF, Mulcahy-Singh EM, Hudson JB, Beggs S, Griffin P, et al., 'Identification of two immune system changes that may contribute to infectious pathology in cystic fibrosis', BacPath 2013, October 2013, Moreton Island, Australia (2013) [Conference Extract] Co-authors: Mulcahy-Singh EM; Hudson JB; Beggs S; Griffin P; Cooley MA | |
| 2011 | Ali N, Cooley MA, Griffin P, Roddam LF, 'Cross kingdom signaling during P. aeruginosa infection of the CF lung results in a decreased capacity of the host to clear the infection', Proceedings of the National Meeting of the Australian Society of Microbiology, Hobart, pp. 127. (2011) [Conference Extract] Co-authors: Ali N; Cooley MA; Griffin P | |
| 2011 | Alqurni F, Reid DW, Cooley MA, Roddam LF, 'The immune response of cystic fibrosis patients to different P. aeruginosa strains', Proceedings of the National Meeting of the Australian Society of Microbiology, Hobart, pp. 72. (2011) [Conference Extract] Co-authors: Reid DW; Cooley MA | |
| 2011 | Latham R, Roddam LF, Reid DW, 'Monitoring Pseudomonas aeruginosa concentration and virulence gene expression in cystic fibrosis sputum during treatment for exacerbations', Proceedings of the National Meeting of the Australian Society of Microbiology, Hobart, pp. 133. (2011) [Conference Extract] Co-authors: Latham R; Reid DW | |
| 2011 | Roddam LF, Latham R, Reid DW, 'Microbiology and immune modulation during intravenous antibiotic therapy for pulmonary exacerbations of CF', National Meeting of the Australian Society of Microbiology, Hobart, pp. 54. (2011) [Conference Extract] Co-authors: Latham R; Reid DW | |
| 2010 | Roddam LF, Latham R, Reid DW, 'Gene expression analysis of bacterial populations in patient sputum samples during intravenous antibiotic therapy', National Meeting of the Australian Society of Microbiology, Sydney, pp. 70. (2010) [Conference Extract] Co-authors: Latham R; Reid DW | |
| 2009 | Roddam LF, Latham R, Reid DW, 'Gene expression analysis demonstrates that intravenous antibiotic treatment of a chronic lung infection results in reduced bacterial load but increased virulence of surviving bacteria', National Meeting of the Australian Society of Microbiology, Perth, pp. 94-95. (2009) [Conference Extract] Co-authors: Latham R; Reid DW | |
| 2008 | Bradbury RS, Champion AC, Roddam LF, Merritt A, Reid DW, et al., 'A survey of virulence genes in Pseudomonas aeruginosa', Australian Society for Microbiology National Scientific Meeting, Melbourne (2008) [Conference Extract] Co-authors: Bradbury RS; Champion AC; Reid DW | |
| 2008 | Roddam LF, Latham R, Reid DW, 'Role of Pseudomonas in pulmonary exacerbations of CF', Proceedings of the ANZCF Nurses Conference, August, Hobart (2008) [Conference Extract] Co-authors: Latham R; Reid DW | |
| 2006 | Bradbury RS, Champion AC, Roddam LF, Sanderson Kevin, Reid DW, 'Prevalence of exoY and exoS genes in clinical and environmental isolates of Pseudomonas aeruginosa', Australian Society for Microbiology National Scientific Meeting, Gold Coast, pp. P10.14. (2006) [Conference Extract] Co-authors: Bradbury RS; Champion AC; Sanderson Kevin; Reid DW |
Grants & Funding
Dr Roddam has been the recipient of highly competitive research and equipment funding.
Funding Summary
Number of grants
22
Total funding
$1,171,079
Projects
Validation of an antibody panel to identify multiple immune cell subsets in a single low-volume CF blood sample (2022)$9,917
- Description
- We have previously designed and validated a specialised antibody panel to identify eight distinct immune cell populations within one tube, from a small amount of blood. We propose to validate a similar panel using commercially available antibodies, to enable our team to significantly contribute to collaborative cystic fibrosis research.
- Funding
- Royal Hobart Hospital Research Foundation ($9,917)
- Scheme
- Grant-Incubator
- Administered By
- University of Tasmania
- Research Team
- Roddam LF; Saxby N; Mulcahy E; Beggs S; Pagnon JC
- Year
- 2022
Is Pandoraea a pathogen? (2022)$24,514
- Description
- Pandoraea is increasingly being isolated from the lungs of people with cystic fibrosis, globally and in Tasmania, but is of unknown clinical significance. This project will investigate whether Pandoraea is a pathogen that causes inflammation and lung tissue damage in vivo and is therefore a pathogen.
- Funding
- The MPST Foundation Ltd ($24,514)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Roddam LF
- Year
- 2022
Testing rhPON2 as a therapy for Pseudomonas aeruginosa infections in CF patients (2021 - 2023)$124,355
- Description
- This project aims to demonstrate that rhPON2 treatment will protect immune cells from AHL-mediated damage and dysfunction effectively augmenting the immune system and facilitating bacterial clearance in vivo.
- Funding
- Vertex Pharmaceuticals Incorporated ($124,355)
- Scheme
- Grant-Mentored Research Innovation Award
- Administered By
- University of Tasmania
- Research Team
- Pagnon JC; Roddam LF
- Period
- 2021 - 2023
Characterisation of newly identified Pandoraea isolates from paediatric Tasmanian CF patients (2020)$8,550
- Description
- Pandoraea, an emerging bacterial pathogen, is highly antibiotic resistant and was first isolated from a Tasmanian CF patient in 2012, then again in 2018 from two Tasmanian paediatric patients. We will characterise these new isolates (determine species, antibiotic resistance profiles and virulence potential) to advance our understanding of this pathogen.
- Funding
- Royal Hobart Hospital Research Foundation ($8,550)
- Scheme
- Grant-Incubator
- Administered By
- University of Tasmania
- Research Team
- Roddam LF; Ambrose M; Pagnon JC; McEwan B; Beggs S
- Year
- 2020
Prevention of bacterial induced immune dysfunction in people with cystic fibrosis (2020)$24,000
- Description
- This project will investigate the nature of infection related immune dysfunction in people with cystic fibrosis and test a new therapeutic for its ability to prevent this dysfunction, effectively augmenting the immune system.
- Funding
- The MPST Foundation Ltd ($24,000)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Roddam LF
- Year
- 2020
Non-conventional antimicrobial testing of emerging pathogens (2017)$10,000
- Description
- Pandoraea, is an emerging bacterial pathogen of cystic fibrosis. Conventional antibiotic susceptibility testing shows Pandoraea to be multi-drug resistant with limited treatment options. We will investigate the antibiotic susceptibility of Pandoraea using non-conventional methods to determine if we are underestimating treatment options for this chronic infection.
- Funding
- Royal Hobart Hospital Research Foundation ($10,000)
- Scheme
- Grant-Starter
- Administered By
- University of Tasmania
- Research Team
- Roddam LF; Beggs S; Ambrose M; Malley RC
- Year
- 2017
Anti-inflammatory efficacy of Marinovas Fucoidan & interactions with microbiota (2016)$100,000
- Description
- Industry interaction to develop Marinova's fucoidan extracts for gut health
- Funding
- Department of Industry, Innovation and Science ($50,000); Marinova Pty Ltd ($50,000)
- Scheme
- Contract Research
- Administered By
- University of Tasmania
- Research Team
- Guven N; Eri RD; Ahuja KDK; Ball MJ; Ambrose M; Roddam LF; Zosky GR
- Year
- 2016
Prevalence and virulence of an emerging bacterial pathogen of Tasmanian cystic fibrosis patients (2015)$11,100
- Description
- Pandoraea, an emerging bacterial pathogen of cystic fibrosis is difficult to identify, is of unknown clinical significance and was recently isolated from a Tasmanian CF patient. we will investigate the prevalence of Pandoraea in Tasmanian CF patients, describe its virulence potential and investigate its susceptilility to our new antimicrobial therapy.
- Funding
- Royal Hobart Hospital Research Foundation ($11,100)
- Scheme
- Grant-Clinical Research
- Administered By
- University of Tasmania
- Research Team
- Roddam LF; Ambrose M; Beggs S; Cooley MA; Malley RC; Warren SJ; Wilson RR; McEwan B
- Year
- 2015
Demonstration of the efficacy of a new therapy against lung infections in a mouse model (2014)$14,500
- Funding
- University of Tasmania ($14,500)
- Scheme
- Grant-Research Enhancement (REGS)
- Administered By
- University of Tasmania
- Research Team
- Roddam LF
- Year
- 2014
A human paraoxonase 2-based therapy for cystic fibrosis A (2014 - 2016)$15,000
- Description
- Cystic Fibrosis (CF) is the most common genetic condition affecting Australians. People with CF carry a mutation in a gene, which is essential for maintaining the proper balance of salt and water in lungs. As a result, CF patients experience a continuous build-up of thick and sticky mucous in their lungs, which can be colonised by many different types of microorganisms, and especially by Pseudomonas aeruginosa. Infections by P. aeruginosa cannot be completely eradicated using currently available antibiotics because cells of this organism can group together to live in so-called biofilms (which are essentially protected cell communities), which antibiotics simply fail to penetrate successfully. This project will investigate ways to make P. aeruginosa more susceptible to existing antibiotics. The approach aims to prevent/disrupt the grouping together of individual bacterial cells in the first instance, thereby allowing the antibiotics to kill them more effectively. Current research is producing in the laboratory a human anti-biofilm enzyme, known as human paraoxonase 2 (PON2). PON2 is usually produced inside of human cells, which means it is not able to attack the bacterial cells that usually live outside human cells. By administering the recombinant human PON2 (as an aerosol, for example), together with certain antibiotics, it is anticipated that prevention and/or eradication of P. aeruginosa infections will be possible in people with CF.
- Funding
- Australian Cystic Fibrosis Research Trust ($15,000)
- Scheme
- Scholarship-Top-Up
- Administered By
- University of Tasmania
- Research Team
- Roddam LF; Cooley MA; Ambrose M
- Period
- 2014 - 2016
Testing a new therapy against lung infections for people with cystic fibrosis (2013)$67,782
- Description
- P. aeruginosa uses small diffusible signal molecules called acyl-homoserine lactones (AHLs) to alter its growth, which enables it to hide from antibiotic therapies and the immune system of the host thereby preventing its eradication from the lungs. These bacterial AHL molecules can also enter and affect human cells leading to further lung damage. This project aims to demonstrate that a novel therapy that inactivates bacterial AHLs can protect human cells from these molecules. Demonstration of this is the first step in showing that this therapy can protect the lungs of people with CF from P. aeruginosa infections. In summary, this new treatment approach should at a minimum prevent a significant amount of the lung damage that occurs, resulting in better quality of life and increased life span. More importantly, this therapy also has the potential to prevent P. aeruginosa lung infections in CF.
- Funding
- Clifford Craig Foundation ($67,782)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Roddam LF; Cooley MA; Ambrose M; Tristram SG
- Year
- 2013
Do adaptive regulatory cells or activated T cells dominate in cystic fibrosis? (2012)$8,228
- Funding
- Royal Hobart Hospital Research Foundation ($8,228)
- Scheme
- Grant-Starter
- Administered By
- University of Tasmania
- Research Team
- Beggs S; Cooley MA; Roddam LF; Korner H; Stock D
- Year
- 2012
2012: The Australian Society for Microbiology 2012 Annual Specific Meeting, Brisbane (2012)$600
- Funding
- University of Tasmania ($600)
- Scheme
- Grant-Conference Support Scheme
- Administered By
- University of Tasmania
- Research Team
- Roddam LF
- Year
- 2012
Identification of a New Target for Therapy in Cystic Fibrosis Lung Infections (2011 - 2012)$20,661
- Funding
- Royal Hobart Hospital Research Foundation ($20,661)
- Scheme
- Grant-Research
- Administered By
- University of Tasmania
- Research Team
- Cooley MA; Roddam LF; Wood-Baker R; Griffin P; Beggs S
- Period
- 2011 - 2012
PPAR-gamma as a therapeutic target in cystic fibrosis and chronic obstructive pulmonary disease (2010)$8,000
- Funding
- Royal Hobart Hospital Research Foundation ($8,000)
- Scheme
- Grant-Starter
- Administered By
- University of Tasmania
- Research Team
- Cooley MA; Roddam LF; Wood-Baker R; Reid DW
- Year
- 2010
Clinical research equipment to accelerate research outputs in molecular and genetic studies (2010)$156,436
- Funding
- Royal Hobart Hospital Research Foundation ($156,436)
- Scheme
- Grant-Equipment
- Administered By
- University of Tasmania
- Research Team
- Reid DW; Champion AC; Roddam LF; Walters EH
- Year
- 2010
Pseudomonas infection as an indirect cause of CF related diabetes (2009)$96,097
- Funding
- Australian Cystic Fibrosis Research Trust ($96,097)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Cooley MA; Roddam LF; Reid DW; Jaffe A
- Year
- 2009
Mechanism of exacerbations in cystic fibrosis lung disease (2009 - 2011)$245,750
- Funding
- National Health & Medical Research Council ($245,750)
- Scheme
- Grant-Project
- Administered By
- University of Tasmania
- Research Team
- Reid DW; Lamont IJ; Roddam LF; Camara M; Turner P
- Period
- 2009 - 2011
- Grant Reference
- 544915
Mechanism of worsening lung disease in cystic fibrosis (2009)$18,850
- Funding
- Rebecca L Cooper Medical Research Foundation ($18,850)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Roddam LF; Reid DW; Lamont IJ; Camara M; Turner P; Cooley MA
- Year
- 2009
The Acquisition of New Strains of Non-Typeable Haemophilus Influenzae Is The Leading Cause of Acute Exacerbations in Tasmanian COPD Patients (2007)$43,467
- Funding
- Clifford Craig Foundation ($43,467)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Roddam LF; Sanderson K; Wood-Baker R; Tristram SG; Haug G
- Year
- 2007
Pseudomonas Aeruginosa Isolated from Cystic Fibrosis Patients (2006 - 2007)$127,272
- Funding
- Royal Hobart Hospital Research Foundation ($127,272)
- Scheme
- Fellowship-Postdoctoral Research
- Administered By
- University of Tasmania
- Research Team
- Roddam LF
- Period
- 2006 - 2007
Investigation of Antibiotic Sensitivity & Virulence Factors of the Tasmanian Clonal Strain of Pseudomonas aeuruginosa Isolated from Cystic Fibrosis Patients (2005)$36,000
- Funding
- Clifford Craig Foundation ($36,000)
- Scheme
- Grant
- Administered By
- University of Tasmania
- Research Team
- Roddam LF; Reid DW; Champion AC; Tristram SG
- Year
- 2005
Research Supervision
Dr Roddam has supervised several PhD and Honours students to completion.
Completed
7
Completed
| Degree | Title | Completed |
|---|---|---|
| PhD | Recombinant Human Paraoxonase-2 as a Therapy to Diminish Pseudomonas Aeruginosa Virulence and Protect Host Cells from Infection Candidate: Simone Anne Page | 2022 |
| PhD | The Regional Lung Response to Mechanical Ventilation Candidate: Seiha Yen | 2019 |
| PhD | The Potential Therapeutic Benefits of rhPON2 Against Pseudomonas Aeruginosa Infections Candidate: Joanne Carmen Pagnon | 2018 |
| PhD | Peripheral Immune Cell Abnormalities Associated with Cystic Fibrosis Candidate: Emily Margery Mulcahy | 2017 |
| PhD | Potential of Human PON2 as an Anti-Pseudomonal Therapy Candidate: Naseem Mohammad Ali | 2015 |
| PhD | Regulation of the LIFR and gp130 Genes by the RUNX1 Transcription Factor Candidate: Abeer Ahmed Qadi | 2012 |
| PhD | Insights into the Nature and Immune Escape of a Transmissible Cancer in Tasmanian Devils Candidate: Cesar Dario Tovar Lopez | 2012 |